Sakar Healthcare Ltd's Q4FY25 Quarter Results
- 16 May 2025
Result Summary
- Sakar Healthcare Ltd reported a 0.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 3.2%.
- Its expenses for the quarter were up by 2.2% QoQ and 1.2% YoY.
- The net profit decreased 31.1% QoQ and decreased 20.4% YoY.
- The earnings per share (EPS) of Sakar Healthcare Ltd stood at 1.4 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 43.83 | 43.71 | 42.47 | 0.3% | 3.2% |
Total Expenses | 39.04 | 38.19 | 38.57 | 2.2% | 1.2% |
Profit Before Tax | 4.80 | 5.48 | 3.89 | -12.4% | 23.4% |
Tax | 1.67 | 0.94 | -0.03 | 77.7% | -5666.7% |
Profit After Tax | 3.12 | 4.53 | 3.92 | -31.1% | -20.4% |
Earnings Per Share | 1.40 | 2.10 | 2.00 | -33.3% | -30.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sakar Healthcare Ltd is a company that operates in the pharmaceutical industry, focusing on the development, manufacturing, and marketing of a wide range of pharmaceutical formulations. The company is involved in producing various dosage forms, including tablets, capsules, injectables, ointments, and syrups. Sakar Healthcare serves both domestic and international markets, supplying high-quality pharmaceutical products. As of the data available up to October 2023, there are no specific recent major developments provided for Sakar Healthcare Ltd. Therefore, any further insights into recent activities or strategic changes within the company are not available based on the current dataset.
Revenue
For the fourth quarter of the fiscal year 2025, Sakar Healthcare Ltd reported a total income of ₹43.83 crores. This represents a marginal quarter-over-quarter (QoQ) increase of 0.3% compared to ₹43.71 crores in Q3FY25. On a year-over-year (YoY) basis, the total income increased by 3.2% from ₹42.47 crores in Q4FY24. This steady growth in revenue suggests a positive trajectory in the company's income generation over the last year, indicating an ability to maintain and slightly enhance its revenue stream in a competitive market environment.
Profitability
Sakar Healthcare Ltd's profitability metrics for Q4FY25 reveal some fluctuations. The Profit Before Tax (PBT) for the quarter stood at ₹4.80 crores, which marks a significant decline of 12.4% QoQ from ₹5.48 crores in Q3FY25. However, YoY, there is a notable increase of 23.4% compared to ₹3.89 crores in Q4FY24. The tax expense for Q4FY25 was ₹1.67 crores, exhibiting a substantial rise of 77.7% QoQ and a dramatic change from a tax credit of ₹-0.03 crores in Q4FY24, indicating a shift in tax liabilities. Consequently, the Profit After Tax (PAT) decreased by 31.1% QoQ to ₹3.12 crores from ₹4.53 crores in Q3FY25, and also witnessed a YoY decline of 20.4% from ₹3.92 crores in Q4FY24. Earnings Per Share (EPS) followed a similar trend, decreasing by 33.3% QoQ to ₹1.40 from ₹2.10 in Q3FY25, and 30.0% YoY from ₹2.00 in Q4FY24.
Operating Metrics
The operating metrics reflect the cost dynamics faced by Sakar Healthcare Ltd. Total Expenses for Q4FY25 amounted to ₹39.04 crores, reflecting a QoQ increase of 2.2% from ₹38.19 crores in Q3FY25. Comparing YoY, the expenses increased by 1.2% from ₹38.57 crores in Q4FY24. This indicates a rising cost structure, which might be linked to inflationary pressures or increased operational scales. The financial ratios such as debt-to-equity ratio, current ratio, or P/E ratio cannot be computed with the provided data since it does not include details on equity, liabilities, or market capitalization. The notable increase in tax liabilities and the corresponding impact on net profitability are significant considerations in understanding the company's operational efficiency and fiscal strategies.